nodes	percent_of_prediction	percent_of_DWPC	metapath
Dabrafenib—BRAF—colon cancer	0.43	0.844	CbGaD
Dabrafenib—ABCB1—colon cancer	0.0796	0.156	CbGaD
Dabrafenib—SLCO1B1—Irinotecan—colon cancer	0.0403	0.136	CbGbCtD
Dabrafenib—SLCO1B3—Methotrexate—colon cancer	0.0366	0.124	CbGbCtD
Dabrafenib—ABCG2—Irinotecan—colon cancer	0.032	0.108	CbGbCtD
Dabrafenib—ABCG2—Fluorouracil—colon cancer	0.0307	0.104	CbGbCtD
Dabrafenib—ABCG2—Vincristine—colon cancer	0.028	0.0944	CbGbCtD
Dabrafenib—SLCO1B1—Methotrexate—colon cancer	0.0213	0.072	CbGbCtD
Dabrafenib—SLC22A8—Methotrexate—colon cancer	0.0197	0.0664	CbGbCtD
Dabrafenib—ABCG2—Methotrexate—colon cancer	0.0169	0.0572	CbGbCtD
Dabrafenib—CYP2C8—Fluorouracil—colon cancer	0.0164	0.0552	CbGbCtD
Dabrafenib—SLC22A6—Methotrexate—colon cancer	0.0137	0.0463	CbGbCtD
Dabrafenib—ABCB1—Irinotecan—colon cancer	0.0115	0.0389	CbGbCtD
Dabrafenib—ABCB1—Vincristine—colon cancer	0.0101	0.034	CbGbCtD
Dabrafenib—CYP3A4—Irinotecan—colon cancer	0.00691	0.0233	CbGbCtD
Dabrafenib—ABCB1—Methotrexate—colon cancer	0.0061	0.0206	CbGbCtD
Dabrafenib—CYP3A4—Vincristine—colon cancer	0.00604	0.0204	CbGbCtD
Dabrafenib—RAF1—Topotecan—Irinotecan—colon cancer	0.00311	1	CbGdCrCtD
Dabrafenib—LIMK1—vagina—colon cancer	0.00152	0.0578	CbGeAlD
Dabrafenib—NEK11—lymph node—colon cancer	0.00137	0.0522	CbGeAlD
Dabrafenib—RAF1—embryo—colon cancer	0.00114	0.0434	CbGeAlD
Dabrafenib—SIK1—renal system—colon cancer	0.00108	0.0412	CbGeAlD
Dabrafenib—LIMK1—lymph node—colon cancer	0.000981	0.0374	CbGeAlD
Dabrafenib—BRAF—bone marrow—colon cancer	0.000978	0.0372	CbGeAlD
Dabrafenib—BRAF—vagina—colon cancer	0.000937	0.0357	CbGeAlD
Dabrafenib—RAF1—epithelium—colon cancer	0.000929	0.0354	CbGeAlD
Dabrafenib—SIK1—lymphoid tissue—colon cancer	0.000899	0.0342	CbGeAlD
Dabrafenib—RAF1—smooth muscle tissue—colon cancer	0.000895	0.0341	CbGeAlD
Dabrafenib—RAF1—renal system—colon cancer	0.000862	0.0328	CbGeAlD
Dabrafenib—SIK1—bone marrow—colon cancer	0.000819	0.0312	CbGeAlD
Dabrafenib—SLCO1B3—vagina—colon cancer	0.000807	0.0308	CbGeAlD
Dabrafenib—BRAF—liver—colon cancer	0.00079	0.0301	CbGeAlD
Dabrafenib—RAF1—lymphoid tissue—colon cancer	0.000716	0.0273	CbGeAlD
Dabrafenib—RAF1—digestive system—colon cancer	0.000707	0.0269	CbGeAlD
Dabrafenib—SLCO1B3—liver—colon cancer	0.000681	0.0259	CbGeAlD
Dabrafenib—SIK1—liver—colon cancer	0.000662	0.0252	CbGeAlD
Dabrafenib—RAF1—bone marrow—colon cancer	0.000652	0.0248	CbGeAlD
Dabrafenib—SLCO1B1—renal system—colon cancer	0.000645	0.0246	CbGeAlD
Dabrafenib—RAF1—vagina—colon cancer	0.000624	0.0238	CbGeAlD
Dabrafenib—BRAF—lymph node—colon cancer	0.000606	0.0231	CbGeAlD
Dabrafenib—SLCO1B1—digestive system—colon cancer	0.000529	0.0201	CbGeAlD
Dabrafenib—RAF1—liver—colon cancer	0.000527	0.0201	CbGeAlD
Dabrafenib—SIK1—lymph node—colon cancer	0.000507	0.0193	CbGeAlD
Dabrafenib—SLC22A8—renal system—colon cancer	0.000501	0.0191	CbGeAlD
Dabrafenib—RAF1—lymph node—colon cancer	0.000404	0.0154	CbGeAlD
Dabrafenib—SLCO1B1—liver—colon cancer	0.000394	0.015	CbGeAlD
Dabrafenib—ABCB1—blood vessel—colon cancer	0.000389	0.0148	CbGeAlD
Dabrafenib—CYP2C8—renal system—colon cancer	0.000367	0.014	CbGeAlD
Dabrafenib—Dry skin—Fluorouracil—colon cancer	0.000311	0.00402	CcSEcCtD
Dabrafenib—Nasopharyngitis—Fluorouracil—colon cancer	0.000303	0.00392	CcSEcCtD
Dabrafenib—Pancreatitis—Irinotecan—colon cancer	0.0003	0.00388	CcSEcCtD
Dabrafenib—Neoplasm—Capecitabine—colon cancer	0.000295	0.00381	CcSEcCtD
Dabrafenib—Neutropenia—Vincristine—colon cancer	0.000294	0.0038	CcSEcCtD
Dabrafenib—Neutropenia—Irinotecan—colon cancer	0.000286	0.0037	CcSEcCtD
Dabrafenib—Stomatitis—Vincristine—colon cancer	0.000273	0.00353	CcSEcCtD
Dabrafenib—Blood alkaline phosphatase increased—Capecitabine—colon cancer	0.000272	0.00352	CcSEcCtD
Dabrafenib—ABCG2—bone marrow—colon cancer	0.00027	0.0103	CbGeAlD
Dabrafenib—Bone disorder—Methotrexate—colon cancer	0.000269	0.00348	CcSEcCtD
Dabrafenib—Renal failure—Irinotecan—colon cancer	0.000268	0.00346	CcSEcCtD
Dabrafenib—Hyperbilirubinaemia—Methotrexate—colon cancer	0.000267	0.00345	CcSEcCtD
Dabrafenib—Stomatitis—Irinotecan—colon cancer	0.000266	0.00344	CcSEcCtD
Dabrafenib—CYP2C8—vagina—colon cancer	0.000266	0.0101	CbGeAlD
Dabrafenib—Infestation NOS—Fluorouracil—colon cancer	0.000261	0.00338	CcSEcCtD
Dabrafenib—Infestation—Fluorouracil—colon cancer	0.000261	0.00338	CcSEcCtD
Dabrafenib—ABCG2—vagina—colon cancer	0.000258	0.00983	CbGeAlD
Dabrafenib—Renal failure acute—Capecitabine—colon cancer	0.000256	0.00332	CcSEcCtD
Dabrafenib—Stomatitis—Fluorouracil—colon cancer	0.000254	0.00329	CcSEcCtD
Dabrafenib—Urinary tract infection—Fluorouracil—colon cancer	0.000254	0.00328	CcSEcCtD
Dabrafenib—CYP3A4—renal system—colon cancer	0.000248	0.00946	CbGeAlD
Dabrafenib—Urinary tract disorder—Vincristine—colon cancer	0.000248	0.00321	CcSEcCtD
Dabrafenib—Dermatitis bullous—Capecitabine—colon cancer	0.000248	0.0032	CcSEcCtD
Dabrafenib—Connective tissue disorder—Vincristine—colon cancer	0.000247	0.00319	CcSEcCtD
Dabrafenib—Urethral disorder—Vincristine—colon cancer	0.000246	0.00318	CcSEcCtD
Dabrafenib—Epistaxis—Fluorouracil—colon cancer	0.000246	0.00318	CcSEcCtD
Dabrafenib—Haemoglobin—Irinotecan—colon cancer	0.000246	0.00318	CcSEcCtD
Dabrafenib—Haemorrhage—Irinotecan—colon cancer	0.000245	0.00316	CcSEcCtD
Dabrafenib—Connective tissue disorder—Irinotecan—colon cancer	0.00024	0.00311	CcSEcCtD
Dabrafenib—Hyponatraemia—Capecitabine—colon cancer	0.000238	0.00307	CcSEcCtD
Dabrafenib—Pain in extremity—Capecitabine—colon cancer	0.000237	0.00306	CcSEcCtD
Dabrafenib—Haemoglobin—Fluorouracil—colon cancer	0.000236	0.00305	CcSEcCtD
Dabrafenib—Haemorrhage—Fluorouracil—colon cancer	0.000234	0.00303	CcSEcCtD
Dabrafenib—ABCB1—embryo—colon cancer	0.000232	0.00884	CbGeAlD
Dabrafenib—Angiopathy—Vincristine—colon cancer	0.000228	0.00295	CcSEcCtD
Dabrafenib—Mediastinal disorder—Vincristine—colon cancer	0.000226	0.00293	CcSEcCtD
Dabrafenib—CYP2C8—liver—colon cancer	0.000224	0.00853	CbGeAlD
Dabrafenib—Alopecia—Vincristine—colon cancer	0.000222	0.00287	CcSEcCtD
Dabrafenib—Angiopathy—Irinotecan—colon cancer	0.000222	0.00287	CcSEcCtD
Dabrafenib—Blood creatinine increased—Capecitabine—colon cancer	0.000222	0.00287	CcSEcCtD
Dabrafenib—Immune system disorder—Irinotecan—colon cancer	0.000221	0.00286	CcSEcCtD
Dabrafenib—Mediastinal disorder—Irinotecan—colon cancer	0.000221	0.00285	CcSEcCtD
Dabrafenib—Dehydration—Capecitabine—colon cancer	0.00022	0.00285	CcSEcCtD
Dabrafenib—Mental disorder—Vincristine—colon cancer	0.00022	0.00285	CcSEcCtD
Dabrafenib—Chills—Irinotecan—colon cancer	0.00022	0.00284	CcSEcCtD
Dabrafenib—Neoplasm—Methotrexate—colon cancer	0.00022	0.00284	CcSEcCtD
Dabrafenib—Arrhythmia—Irinotecan—colon cancer	0.000219	0.00283	CcSEcCtD
Dabrafenib—ABCG2—liver—colon cancer	0.000218	0.0083	CbGeAlD
Dabrafenib—Dry skin—Capecitabine—colon cancer	0.000217	0.00281	CcSEcCtD
Dabrafenib—Alopecia—Irinotecan—colon cancer	0.000216	0.0028	CcSEcCtD
Dabrafenib—Abdominal pain upper—Capecitabine—colon cancer	0.000216	0.0028	CcSEcCtD
Dabrafenib—Hypokalaemia—Capecitabine—colon cancer	0.000215	0.00279	CcSEcCtD
Dabrafenib—Aspartate aminotransferase increased—Capecitabine—colon cancer	0.000213	0.00276	CcSEcCtD
Dabrafenib—Nasopharyngitis—Capecitabine—colon cancer	0.000212	0.00274	CcSEcCtD
Dabrafenib—Back pain—Vincristine—colon cancer	0.000212	0.00274	CcSEcCtD
Dabrafenib—Arrhythmia—Fluorouracil—colon cancer	0.000209	0.00271	CcSEcCtD
Dabrafenib—Alanine aminotransferase increased—Capecitabine—colon cancer	0.000209	0.0027	CcSEcCtD
Dabrafenib—Alopecia—Fluorouracil—colon cancer	0.000207	0.00268	CcSEcCtD
Dabrafenib—Back pain—Irinotecan—colon cancer	0.000206	0.00266	CcSEcCtD
Dabrafenib—Muscle spasms—Irinotecan—colon cancer	0.000205	0.00265	CcSEcCtD
Dabrafenib—Erythema—Fluorouracil—colon cancer	0.000204	0.00264	CcSEcCtD
Dabrafenib—CYP3A4—digestive system—colon cancer	0.000204	0.00776	CbGeAlD
Dabrafenib—Anaemia—Vincristine—colon cancer	0.000202	0.00261	CcSEcCtD
Dabrafenib—Anaemia—Irinotecan—colon cancer	0.000197	0.00255	CcSEcCtD
Dabrafenib—Abdominal discomfort—Capecitabine—colon cancer	0.000196	0.00254	CcSEcCtD
Dabrafenib—Leukopenia—Vincristine—colon cancer	0.000196	0.00253	CcSEcCtD
Dabrafenib—Vision blurred—Fluorouracil—colon cancer	0.000192	0.00249	CcSEcCtD
Dabrafenib—Neutropenia—Capecitabine—colon cancer	0.000191	0.00247	CcSEcCtD
Dabrafenib—Renal failure acute—Methotrexate—colon cancer	0.000191	0.00247	CcSEcCtD
Dabrafenib—Leukopenia—Irinotecan—colon cancer	0.000191	0.00247	CcSEcCtD
Dabrafenib—ABCB1—epithelium—colon cancer	0.00019	0.00722	CbGeAlD
Dabrafenib—Hypertension—Vincristine—colon cancer	0.000189	0.00244	CcSEcCtD
Dabrafenib—Anaemia—Fluorouracil—colon cancer	0.000189	0.00244	CcSEcCtD
Dabrafenib—Myalgia—Vincristine—colon cancer	0.000186	0.00241	CcSEcCtD
Dabrafenib—Cough—Irinotecan—colon cancer	0.000186	0.0024	CcSEcCtD
Dabrafenib—Hyperglycaemia—Capecitabine—colon cancer	0.000185	0.00239	CcSEcCtD
Dabrafenib—Hypertension—Irinotecan—colon cancer	0.000184	0.00238	CcSEcCtD
Dabrafenib—Leukopenia—Fluorouracil—colon cancer	0.000183	0.00236	CcSEcCtD
Dabrafenib—Infestation NOS—Capecitabine—colon cancer	0.000182	0.00236	CcSEcCtD
Dabrafenib—Infestation—Capecitabine—colon cancer	0.000182	0.00236	CcSEcCtD
Dabrafenib—Renal failure—Capecitabine—colon cancer	0.000179	0.00232	CcSEcCtD
Dabrafenib—Oedema—Vincristine—colon cancer	0.000179	0.00231	CcSEcCtD
Dabrafenib—Stomatitis—Capecitabine—colon cancer	0.000178	0.0023	CcSEcCtD
Dabrafenib—Infection—Vincristine—colon cancer	0.000177	0.00229	CcSEcCtD
Dabrafenib—Urinary tract infection—Capecitabine—colon cancer	0.000177	0.00229	CcSEcCtD
Dabrafenib—ABCB1—renal system—colon cancer	0.000176	0.00669	CbGeAlD
Dabrafenib—Nervous system disorder—Vincristine—colon cancer	0.000175	0.00226	CcSEcCtD
Dabrafenib—Thrombocytopenia—Vincristine—colon cancer	0.000175	0.00226	CcSEcCtD
Dabrafenib—Haematuria—Capecitabine—colon cancer	0.000174	0.00225	CcSEcCtD
Dabrafenib—Oedema—Irinotecan—colon cancer	0.000174	0.00225	CcSEcCtD
Dabrafenib—Myalgia—Fluorouracil—colon cancer	0.000174	0.00225	CcSEcCtD
Dabrafenib—Infection—Irinotecan—colon cancer	0.000173	0.00223	CcSEcCtD
Dabrafenib—Hyperhidrosis—Vincristine—colon cancer	0.000173	0.00223	CcSEcCtD
Dabrafenib—Epistaxis—Capecitabine—colon cancer	0.000172	0.00223	CcSEcCtD
Dabrafenib—Nervous system disorder—Irinotecan—colon cancer	0.00017	0.0022	CcSEcCtD
Dabrafenib—Thrombocytopenia—Irinotecan—colon cancer	0.00017	0.0022	CcSEcCtD
Dabrafenib—Hyperhidrosis—Irinotecan—colon cancer	0.000168	0.00217	CcSEcCtD
Dabrafenib—ABCG2—lymph node—colon cancer	0.000167	0.00636	CbGeAlD
Dabrafenib—Hypotension—Vincristine—colon cancer	0.000167	0.00216	CcSEcCtD
Dabrafenib—Oedema—Fluorouracil—colon cancer	0.000167	0.00215	CcSEcCtD
Dabrafenib—Infection—Fluorouracil—colon cancer	0.000165	0.00214	CcSEcCtD
Dabrafenib—Haemoglobin—Capecitabine—colon cancer	0.000165	0.00213	CcSEcCtD
Dabrafenib—Haemorrhage—Capecitabine—colon cancer	0.000164	0.00212	CcSEcCtD
Dabrafenib—Nervous system disorder—Fluorouracil—colon cancer	0.000163	0.00211	CcSEcCtD
Dabrafenib—Thrombocytopenia—Fluorouracil—colon cancer	0.000163	0.00211	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Vincristine—colon cancer	0.000163	0.0021	CcSEcCtD
Dabrafenib—Hypotension—Irinotecan—colon cancer	0.000162	0.0021	CcSEcCtD
Dabrafenib—Urinary tract disorder—Capecitabine—colon cancer	0.000162	0.00209	CcSEcCtD
Dabrafenib—Insomnia—Vincristine—colon cancer	0.000161	0.00209	CcSEcCtD
Dabrafenib—Oedema peripheral—Capecitabine—colon cancer	0.000161	0.00209	CcSEcCtD
Dabrafenib—Connective tissue disorder—Capecitabine—colon cancer	0.000161	0.00208	CcSEcCtD
Dabrafenib—Urethral disorder—Capecitabine—colon cancer	0.000161	0.00208	CcSEcCtD
Dabrafenib—Insomnia—Irinotecan—colon cancer	0.000157	0.00203	CcSEcCtD
Dabrafenib—Hypotension—Fluorouracil—colon cancer	0.000156	0.00201	CcSEcCtD
Dabrafenib—Decreased appetite—Vincristine—colon cancer	0.000155	0.00201	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Vincristine—colon cancer	0.000154	0.00199	CcSEcCtD
Dabrafenib—Fatigue—Vincristine—colon cancer	0.000154	0.00199	CcSEcCtD
Dabrafenib—Eye disorder—Capecitabine—colon cancer	0.000153	0.00198	CcSEcCtD
Dabrafenib—Constipation—Vincristine—colon cancer	0.000153	0.00197	CcSEcCtD
Dabrafenib—CYP3A4—liver—colon cancer	0.000152	0.00578	CbGeAlD
Dabrafenib—Musculoskeletal discomfort—Fluorouracil—colon cancer	0.000152	0.00196	CcSEcCtD
Dabrafenib—Decreased appetite—Irinotecan—colon cancer	0.000151	0.00195	CcSEcCtD
Dabrafenib—Insomnia—Fluorouracil—colon cancer	0.000151	0.00195	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Irinotecan—colon cancer	0.00015	0.00194	CcSEcCtD
Dabrafenib—Fatigue—Irinotecan—colon cancer	0.00015	0.00194	CcSEcCtD
Dabrafenib—Pancreatitis—Methotrexate—colon cancer	0.000149	0.00193	CcSEcCtD
Dabrafenib—Constipation—Irinotecan—colon cancer	0.000149	0.00192	CcSEcCtD
Dabrafenib—Angiopathy—Capecitabine—colon cancer	0.000149	0.00192	CcSEcCtD
Dabrafenib—Immune system disorder—Capecitabine—colon cancer	0.000148	0.00191	CcSEcCtD
Dabrafenib—Mediastinal disorder—Capecitabine—colon cancer	0.000148	0.00191	CcSEcCtD
Dabrafenib—Chills—Capecitabine—colon cancer	0.000147	0.0019	CcSEcCtD
Dabrafenib—Arrhythmia—Capecitabine—colon cancer	0.000146	0.00189	CcSEcCtD
Dabrafenib—Abdominal discomfort—Methotrexate—colon cancer	0.000146	0.00189	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Vincristine—colon cancer	0.000146	0.00189	CcSEcCtD
Dabrafenib—ABCB1—lymphoid tissue—colon cancer	0.000146	0.00556	CbGeAlD
Dabrafenib—Decreased appetite—Fluorouracil—colon cancer	0.000145	0.00187	CcSEcCtD
Dabrafenib—Alopecia—Capecitabine—colon cancer	0.000145	0.00187	CcSEcCtD
Dabrafenib—ABCB1—digestive system—colon cancer	0.000144	0.00549	CbGeAlD
Dabrafenib—Gastrointestinal disorder—Fluorouracil—colon cancer	0.000144	0.00186	CcSEcCtD
Dabrafenib—Mental disorder—Capecitabine—colon cancer	0.000143	0.00186	CcSEcCtD
Dabrafenib—Malnutrition—Capecitabine—colon cancer	0.000143	0.00184	CcSEcCtD
Dabrafenib—Erythema—Capecitabine—colon cancer	0.000143	0.00184	CcSEcCtD
Dabrafenib—Neutropenia—Methotrexate—colon cancer	0.000142	0.00184	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Irinotecan—colon cancer	0.000142	0.00184	CcSEcCtD
Dabrafenib—Abdominal pain—Vincristine—colon cancer	0.000141	0.00182	CcSEcCtD
Dabrafenib—Body temperature increased—Vincristine—colon cancer	0.000141	0.00182	CcSEcCtD
Dabrafenib—Back pain—Capecitabine—colon cancer	0.000138	0.00178	CcSEcCtD
Dabrafenib—Abdominal pain—Irinotecan—colon cancer	0.000137	0.00178	CcSEcCtD
Dabrafenib—Body temperature increased—Irinotecan—colon cancer	0.000137	0.00178	CcSEcCtD
Dabrafenib—Muscle spasms—Capecitabine—colon cancer	0.000137	0.00177	CcSEcCtD
Dabrafenib—Infestation—Methotrexate—colon cancer	0.000136	0.00176	CcSEcCtD
Dabrafenib—Infestation NOS—Methotrexate—colon cancer	0.000136	0.00176	CcSEcCtD
Dabrafenib—Vision blurred—Capecitabine—colon cancer	0.000134	0.00174	CcSEcCtD
Dabrafenib—Renal failure—Methotrexate—colon cancer	0.000134	0.00173	CcSEcCtD
Dabrafenib—ABCB1—bone marrow—colon cancer	0.000133	0.00506	CbGeAlD
Dabrafenib—Stomatitis—Methotrexate—colon cancer	0.000132	0.00171	CcSEcCtD
Dabrafenib—Anaemia—Capecitabine—colon cancer	0.000132	0.0017	CcSEcCtD
Dabrafenib—Body temperature increased—Fluorouracil—colon cancer	0.000132	0.0017	CcSEcCtD
Dabrafenib—Hypersensitivity—Vincristine—colon cancer	0.000132	0.0017	CcSEcCtD
Dabrafenib—Haematuria—Methotrexate—colon cancer	0.000129	0.00167	CcSEcCtD
Dabrafenib—Epistaxis—Methotrexate—colon cancer	0.000128	0.00166	CcSEcCtD
Dabrafenib—Hypersensitivity—Irinotecan—colon cancer	0.000128	0.00166	CcSEcCtD
Dabrafenib—Asthenia—Vincristine—colon cancer	0.000128	0.00166	CcSEcCtD
Dabrafenib—Leukopenia—Capecitabine—colon cancer	0.000128	0.00165	CcSEcCtD
Dabrafenib—ABCB1—vagina—colon cancer	0.000127	0.00485	CbGeAlD
Dabrafenib—Asthenia—Irinotecan—colon cancer	0.000125	0.00161	CcSEcCtD
Dabrafenib—Cough—Capecitabine—colon cancer	0.000124	0.00161	CcSEcCtD
Dabrafenib—Hypertension—Capecitabine—colon cancer	0.000123	0.00159	CcSEcCtD
Dabrafenib—Hypersensitivity—Fluorouracil—colon cancer	0.000123	0.00159	CcSEcCtD
Dabrafenib—Haemoglobin—Methotrexate—colon cancer	0.000123	0.00158	CcSEcCtD
Dabrafenib—Diarrhoea—Vincristine—colon cancer	0.000122	0.00158	CcSEcCtD
Dabrafenib—Haemorrhage—Methotrexate—colon cancer	0.000122	0.00158	CcSEcCtD
Dabrafenib—Myalgia—Capecitabine—colon cancer	0.000121	0.00157	CcSEcCtD
Dabrafenib—Arthralgia—Capecitabine—colon cancer	0.000121	0.00157	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—colon cancer	0.000121	0.00156	CcSEcCtD
Dabrafenib—Urinary tract disorder—Methotrexate—colon cancer	0.00012	0.00156	CcSEcCtD
Dabrafenib—Urethral disorder—Methotrexate—colon cancer	0.00012	0.00155	CcSEcCtD
Dabrafenib—Diarrhoea—Irinotecan—colon cancer	0.000119	0.00154	CcSEcCtD
Dabrafenib—Dry mouth—Capecitabine—colon cancer	0.000119	0.00153	CcSEcCtD
Dabrafenib—Dizziness—Vincristine—colon cancer	0.000118	0.00153	CcSEcCtD
Dabrafenib—Pruritus—Fluorouracil—colon cancer	0.000118	0.00152	CcSEcCtD
Dabrafenib—Oedema—Capecitabine—colon cancer	0.000116	0.0015	CcSEcCtD
Dabrafenib—Infection—Capecitabine—colon cancer	0.000116	0.00149	CcSEcCtD
Dabrafenib—Dizziness—Irinotecan—colon cancer	0.000115	0.00149	CcSEcCtD
Dabrafenib—Nervous system disorder—Capecitabine—colon cancer	0.000114	0.00148	CcSEcCtD
Dabrafenib—Eye disorder—Methotrexate—colon cancer	0.000114	0.00147	CcSEcCtD
Dabrafenib—Diarrhoea—Fluorouracil—colon cancer	0.000114	0.00147	CcSEcCtD
Dabrafenib—Thrombocytopenia—Capecitabine—colon cancer	0.000114	0.00147	CcSEcCtD
Dabrafenib—Vomiting—Vincristine—colon cancer	0.000114	0.00147	CcSEcCtD
Dabrafenib—Skin disorder—Capecitabine—colon cancer	0.000113	0.00146	CcSEcCtD
Dabrafenib—Rash—Vincristine—colon cancer	0.000113	0.00146	CcSEcCtD
Dabrafenib—Hyperhidrosis—Capecitabine—colon cancer	0.000112	0.00145	CcSEcCtD
Dabrafenib—Dermatitis—Vincristine—colon cancer	0.000112	0.00145	CcSEcCtD
Dabrafenib—Headache—Vincristine—colon cancer	0.000112	0.00145	CcSEcCtD
Dabrafenib—Angiopathy—Methotrexate—colon cancer	0.000111	0.00143	CcSEcCtD
Dabrafenib—Vomiting—Irinotecan—colon cancer	0.000111	0.00143	CcSEcCtD
Dabrafenib—Immune system disorder—Methotrexate—colon cancer	0.00011	0.00142	CcSEcCtD
Dabrafenib—Dizziness—Fluorouracil—colon cancer	0.00011	0.00142	CcSEcCtD
Dabrafenib—Mediastinal disorder—Methotrexate—colon cancer	0.00011	0.00142	CcSEcCtD
Dabrafenib—Rash—Irinotecan—colon cancer	0.00011	0.00142	CcSEcCtD
Dabrafenib—Dermatitis—Irinotecan—colon cancer	0.00011	0.00142	CcSEcCtD
Dabrafenib—Chills—Methotrexate—colon cancer	0.000109	0.00141	CcSEcCtD
Dabrafenib—Headache—Irinotecan—colon cancer	0.000109	0.00141	CcSEcCtD
Dabrafenib—Hypotension—Capecitabine—colon cancer	0.000109	0.00141	CcSEcCtD
Dabrafenib—Alopecia—Methotrexate—colon cancer	0.000108	0.00139	CcSEcCtD
Dabrafenib—ABCB1—liver—colon cancer	0.000107	0.00409	CbGeAlD
Dabrafenib—Mental disorder—Methotrexate—colon cancer	0.000107	0.00138	CcSEcCtD
Dabrafenib—Malnutrition—Methotrexate—colon cancer	0.000106	0.00137	CcSEcCtD
Dabrafenib—Erythema—Methotrexate—colon cancer	0.000106	0.00137	CcSEcCtD
Dabrafenib—Nausea—Vincristine—colon cancer	0.000106	0.00137	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Capecitabine—colon cancer	0.000106	0.00137	CcSEcCtD
Dabrafenib—Vomiting—Fluorouracil—colon cancer	0.000106	0.00137	CcSEcCtD
Dabrafenib—Insomnia—Capecitabine—colon cancer	0.000105	0.00136	CcSEcCtD
Dabrafenib—Rash—Fluorouracil—colon cancer	0.000105	0.00136	CcSEcCtD
Dabrafenib—Dermatitis—Fluorouracil—colon cancer	0.000105	0.00136	CcSEcCtD
Dabrafenib—Headache—Fluorouracil—colon cancer	0.000104	0.00135	CcSEcCtD
Dabrafenib—Nausea—Irinotecan—colon cancer	0.000103	0.00134	CcSEcCtD
Dabrafenib—Back pain—Methotrexate—colon cancer	0.000103	0.00133	CcSEcCtD
Dabrafenib—Decreased appetite—Capecitabine—colon cancer	0.000101	0.00131	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Capecitabine—colon cancer	0.0001	0.0013	CcSEcCtD
Dabrafenib—Fatigue—Capecitabine—colon cancer	0.0001	0.0013	CcSEcCtD
Dabrafenib—Vision blurred—Methotrexate—colon cancer	0.0001	0.00129	CcSEcCtD
Dabrafenib—Constipation—Capecitabine—colon cancer	9.95e-05	0.00129	CcSEcCtD
Dabrafenib—Nausea—Fluorouracil—colon cancer	9.89e-05	0.00128	CcSEcCtD
Dabrafenib—Anaemia—Methotrexate—colon cancer	9.81e-05	0.00127	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Capecitabine—colon cancer	9.51e-05	0.00123	CcSEcCtD
Dabrafenib—Leukopenia—Methotrexate—colon cancer	9.5e-05	0.00123	CcSEcCtD
Dabrafenib—Cough—Methotrexate—colon cancer	9.26e-05	0.0012	CcSEcCtD
Dabrafenib—Body temperature increased—Capecitabine—colon cancer	9.2e-05	0.00119	CcSEcCtD
Dabrafenib—Abdominal pain—Capecitabine—colon cancer	9.2e-05	0.00119	CcSEcCtD
Dabrafenib—Myalgia—Methotrexate—colon cancer	9.04e-05	0.00117	CcSEcCtD
Dabrafenib—Arthralgia—Methotrexate—colon cancer	9.04e-05	0.00117	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—colon cancer	8.97e-05	0.00116	CcSEcCtD
Dabrafenib—Infection—Methotrexate—colon cancer	8.61e-05	0.00111	CcSEcCtD
Dabrafenib—Hypersensitivity—Capecitabine—colon cancer	8.57e-05	0.00111	CcSEcCtD
Dabrafenib—Nervous system disorder—Methotrexate—colon cancer	8.49e-05	0.0011	CcSEcCtD
Dabrafenib—Thrombocytopenia—Methotrexate—colon cancer	8.48e-05	0.0011	CcSEcCtD
Dabrafenib—Skin disorder—Methotrexate—colon cancer	8.41e-05	0.00109	CcSEcCtD
Dabrafenib—Hyperhidrosis—Methotrexate—colon cancer	8.37e-05	0.00108	CcSEcCtD
Dabrafenib—Asthenia—Capecitabine—colon cancer	8.35e-05	0.00108	CcSEcCtD
Dabrafenib—ABCB1—lymph node—colon cancer	8.24e-05	0.00314	CbGeAlD
Dabrafenib—Pruritus—Capecitabine—colon cancer	8.23e-05	0.00106	CcSEcCtD
Dabrafenib—Hypotension—Methotrexate—colon cancer	8.09e-05	0.00105	CcSEcCtD
Dabrafenib—Diarrhoea—Capecitabine—colon cancer	7.96e-05	0.00103	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Methotrexate—colon cancer	7.89e-05	0.00102	CcSEcCtD
Dabrafenib—Insomnia—Methotrexate—colon cancer	7.83e-05	0.00101	CcSEcCtD
Dabrafenib—Dizziness—Capecitabine—colon cancer	7.69e-05	0.000995	CcSEcCtD
Dabrafenib—Decreased appetite—Methotrexate—colon cancer	7.53e-05	0.000974	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Methotrexate—colon cancer	7.48e-05	0.000967	CcSEcCtD
Dabrafenib—Fatigue—Methotrexate—colon cancer	7.47e-05	0.000966	CcSEcCtD
Dabrafenib—Vomiting—Capecitabine—colon cancer	7.4e-05	0.000957	CcSEcCtD
Dabrafenib—Rash—Capecitabine—colon cancer	7.34e-05	0.000949	CcSEcCtD
Dabrafenib—Dermatitis—Capecitabine—colon cancer	7.33e-05	0.000948	CcSEcCtD
Dabrafenib—Headache—Capecitabine—colon cancer	7.29e-05	0.000943	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Methotrexate—colon cancer	7.08e-05	0.000916	CcSEcCtD
Dabrafenib—Nausea—Capecitabine—colon cancer	6.91e-05	0.000894	CcSEcCtD
Dabrafenib—Abdominal pain—Methotrexate—colon cancer	6.85e-05	0.000885	CcSEcCtD
Dabrafenib—Body temperature increased—Methotrexate—colon cancer	6.85e-05	0.000885	CcSEcCtD
Dabrafenib—Hypersensitivity—Methotrexate—colon cancer	6.38e-05	0.000825	CcSEcCtD
Dabrafenib—Asthenia—Methotrexate—colon cancer	6.21e-05	0.000804	CcSEcCtD
Dabrafenib—Pruritus—Methotrexate—colon cancer	6.13e-05	0.000792	CcSEcCtD
Dabrafenib—Diarrhoea—Methotrexate—colon cancer	5.93e-05	0.000766	CcSEcCtD
Dabrafenib—Dizziness—Methotrexate—colon cancer	5.73e-05	0.000741	CcSEcCtD
Dabrafenib—Vomiting—Methotrexate—colon cancer	5.51e-05	0.000712	CcSEcCtD
Dabrafenib—Rash—Methotrexate—colon cancer	5.46e-05	0.000706	CcSEcCtD
Dabrafenib—Dermatitis—Methotrexate—colon cancer	5.46e-05	0.000706	CcSEcCtD
Dabrafenib—Headache—Methotrexate—colon cancer	5.43e-05	0.000702	CcSEcCtD
Dabrafenib—Nausea—Methotrexate—colon cancer	5.14e-05	0.000665	CcSEcCtD
Dabrafenib—RAF1—Signaling by PDGF—HRAS—colon cancer	2.02e-05	0.000232	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by NGF—SRC—colon cancer	2e-05	0.000229	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	2e-05	0.000229	CbGpPWpGaD
Dabrafenib—RAF1—NGF signalling via TRKA from the plasma membrane—PIK3CA—colon cancer	1.98e-05	0.000227	CbGpPWpGaD
Dabrafenib—RAF1—Insulin Signaling—AKT1—colon cancer	1.98e-05	0.000227	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—EP300—colon cancer	1.98e-05	0.000226	CbGpPWpGaD
Dabrafenib—RAF1—Downstream signal transduction—AKT1—colon cancer	1.97e-05	0.000226	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by FGFR—AKT1—colon cancer	1.96e-05	0.000224	CbGpPWpGaD
Dabrafenib—RAF1—EGF/EGFR Signaling Pathway—AKT1—colon cancer	1.96e-05	0.000224	CbGpPWpGaD
Dabrafenib—RAF1—Cytokine Signaling in Immune system—NRAS—colon cancer	1.96e-05	0.000224	CbGpPWpGaD
Dabrafenib—RAF1—Focal Adhesion—HRAS—colon cancer	1.95e-05	0.000224	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by ERBB2—AKT1—colon cancer	1.95e-05	0.000223	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—FGFR3—colon cancer	1.94e-05	0.000223	CbGpPWpGaD
Dabrafenib—RAF1—DAP12 signaling—AKT1—colon cancer	1.94e-05	0.000222	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by NGF—NRAS—colon cancer	1.93e-05	0.000221	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—SRC—colon cancer	1.92e-05	0.00022	CbGpPWpGaD
Dabrafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—colon cancer	1.91e-05	0.000219	CbGpPWpGaD
Dabrafenib—RAF1—MAPK Signaling Pathway—AKT1—colon cancer	1.9e-05	0.000218	CbGpPWpGaD
Dabrafenib—ABCB1—HIF-1-alpha transcription factor network—AKT1—colon cancer	1.9e-05	0.000217	CbGpPWpGaD
Dabrafenib—RAF1—Transmission across Chemical Synapses—HRAS—colon cancer	1.88e-05	0.000215	CbGpPWpGaD
Dabrafenib—RAF1—Platelet activation, signaling and aggregation—PIK3CA—colon cancer	1.87e-05	0.000214	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—NRAS—colon cancer	1.85e-05	0.000212	CbGpPWpGaD
Dabrafenib—RAF1—NGF signalling via TRKA from the plasma membrane—HRAS—colon cancer	1.83e-05	0.00021	CbGpPWpGaD
Dabrafenib—RAF1—Fc epsilon receptor (FCERI) signaling—AKT1—colon cancer	1.83e-05	0.000209	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by FGFR in disease—AKT1—colon cancer	1.83e-05	0.000209	CbGpPWpGaD
Dabrafenib—RAF1—DAP12 interactions—AKT1—colon cancer	1.83e-05	0.000209	CbGpPWpGaD
Dabrafenib—RAF1—Axon guidance—SRC—colon cancer	1.81e-05	0.000207	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by EGFR—AKT1—colon cancer	1.81e-05	0.000207	CbGpPWpGaD
Dabrafenib—BRAF—Signaling by NGF—AKT1—colon cancer	1.8e-05	0.000206	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by EGFR in Cancer—AKT1—colon cancer	1.79e-05	0.000205	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by PDGF—AKT1—colon cancer	1.79e-05	0.000204	CbGpPWpGaD
Dabrafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—colon cancer	1.77e-05	0.000203	CbGpPWpGaD
Dabrafenib—RAF1—Axon guidance—VEGFA—colon cancer	1.76e-05	0.000202	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by NGF—EGFR—colon cancer	1.75e-05	0.000201	CbGpPWpGaD
Dabrafenib—RAF1—Axon guidance—NRAS—colon cancer	1.74e-05	0.0002	CbGpPWpGaD
Dabrafenib—RAF1—Focal Adhesion—AKT1—colon cancer	1.73e-05	0.000198	CbGpPWpGaD
Dabrafenib—RAF1—Integrated Pancreatic Cancer Pathway—AKT1—colon cancer	1.72e-05	0.000197	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism of lipids and lipoproteins—PPARG—colon cancer	1.71e-05	0.000196	CbGpPWpGaD
Dabrafenib—RAF1—Cytokine Signaling in Immune system—KRAS—colon cancer	1.69e-05	0.000193	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—EGFR—colon cancer	1.69e-05	0.000193	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism of lipids and lipoproteins—EP300—colon cancer	1.66e-05	0.000191	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by NGF—KRAS—colon cancer	1.66e-05	0.00019	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—CDH1—colon cancer	1.64e-05	0.000188	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—ABCB1—colon cancer	1.63e-05	0.000186	CbGpPWpGaD
Dabrafenib—RAF1—NGF signalling via TRKA from the plasma membrane—AKT1—colon cancer	1.62e-05	0.000185	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—colon cancer	1.61e-05	0.000185	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—TYMS—colon cancer	1.6e-05	0.000183	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—KRAS—colon cancer	1.59e-05	0.000182	CbGpPWpGaD
Dabrafenib—RAF1—Axon guidance—EGFR—colon cancer	1.59e-05	0.000182	CbGpPWpGaD
Dabrafenib—BRAF—Disease—FGFR3—colon cancer	1.57e-05	0.00018	CbGpPWpGaD
Dabrafenib—RAF1—Cytokine Signaling in Immune system—PIK3CA—colon cancer	1.55e-05	0.000177	CbGpPWpGaD
Dabrafenib—RAF1—Platelet activation, signaling and aggregation—AKT1—colon cancer	1.53e-05	0.000175	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by NGF—PIK3CA—colon cancer	1.52e-05	0.000174	CbGpPWpGaD
Dabrafenib—RAF1—Axon guidance—KRAS—colon cancer	1.5e-05	0.000172	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—colon cancer	1.5e-05	0.000171	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—PIK3CA—colon cancer	1.46e-05	0.000167	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—colon cancer	1.46e-05	0.000167	CbGpPWpGaD
Dabrafenib—BRAF—Disease—APC—colon cancer	1.45e-05	0.000165	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—colon cancer	1.44e-05	0.000165	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CD8A—colon cancer	1.44e-05	0.000165	CbGpPWpGaD
Dabrafenib—RAF1—Neuronal System—HRAS—colon cancer	1.44e-05	0.000165	CbGpPWpGaD
Dabrafenib—RAF1—Cytokine Signaling in Immune system—HRAS—colon cancer	1.43e-05	0.000164	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—CTNNB1—colon cancer	1.43e-05	0.000164	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—colon cancer	1.41e-05	0.000161	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by NGF—HRAS—colon cancer	1.41e-05	0.000161	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—HRAS—colon cancer	1.35e-05	0.000155	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	1.34e-05	0.000154	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—colon cancer	1.34e-05	0.000154	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—EP300—colon cancer	1.33e-05	0.000152	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—EP300—colon cancer	1.3e-05	0.000149	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—colon cancer	1.3e-05	0.000149	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—SRC—colon cancer	1.29e-05	0.000148	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CHST5—colon cancer	1.28e-05	0.000146	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ODC1—colon cancer	1.28e-05	0.000146	CbGpPWpGaD
Dabrafenib—RAF1—Axon guidance—HRAS—colon cancer	1.28e-05	0.000146	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—colon cancer	1.27e-05	0.000145	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—SRC—colon cancer	1.27e-05	0.000145	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—CTNNB1—colon cancer	1.26e-05	0.000145	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—VEGFA—colon cancer	1.26e-05	0.000144	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by NGF—AKT1—colon cancer	1.24e-05	0.000142	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—NRAS—colon cancer	1.24e-05	0.000142	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—VEGFA—colon cancer	1.24e-05	0.000141	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—CDKN1A—colon cancer	1.23e-05	0.000141	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—BCL2L1—colon cancer	1.23e-05	0.000141	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	1.23e-05	0.000141	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—NRAS—colon cancer	1.22e-05	0.00014	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—AKT1—colon cancer	1.19e-05	0.000137	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—CDKN1A—colon cancer	1.18e-05	0.000136	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—FGFR3—colon cancer	1.18e-05	0.000135	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—EP300—colon cancer	1.17e-05	0.000134	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—colon cancer	1.17e-05	0.000134	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—colon cancer	1.17e-05	0.000133	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—TGFB1—colon cancer	1.16e-05	0.000132	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—colon cancer	1.14e-05	0.000131	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—SRC—colon cancer	1.14e-05	0.000131	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—TGFB1—colon cancer	1.13e-05	0.00013	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—PPARG—colon cancer	1.13e-05	0.00013	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—EGFR—colon cancer	1.13e-05	0.00013	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism of lipids and lipoproteins—EP300—colon cancer	1.12e-05	0.000128	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—FGFR3—colon cancer	1.1e-05	0.000126	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—NRAS—colon cancer	1.1e-05	0.000126	CbGpPWpGaD
Dabrafenib—BRAF—Disease—PTGS2—colon cancer	1.1e-05	0.000126	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—SRC—colon cancer	1.1e-05	0.000126	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—ABCB1—colon cancer	1.09e-05	0.000125	CbGpPWpGaD
Dabrafenib—RAF1—Disease—FGFR3—colon cancer	1.09e-05	0.000125	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—colon cancer	1.08e-05	0.000124	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—TYMS—colon cancer	1.07e-05	0.000123	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—KRAS—colon cancer	1.07e-05	0.000123	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—NRAS—colon cancer	1.05e-05	0.000121	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—KRAS—colon cancer	1.05e-05	0.00012	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—ABCB1—colon cancer	1.01e-05	0.000116	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—APC—colon cancer	1.01e-05	0.000116	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—EGFR—colon cancer	1e-05	0.000115	CbGpPWpGaD
Dabrafenib—RAF1—Disease—APC—colon cancer	1e-05	0.000114	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CDH1—colon cancer	9.97e-06	0.000114	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—TYMS—colon cancer	9.95e-06	0.000114	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—colon cancer	9.92e-06	0.000114	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—colon cancer	9.82e-06	0.000112	CbGpPWpGaD
Dabrafenib—BRAF—Disease—CTNNB1—colon cancer	9.82e-06	0.000112	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—PIK3CA—colon cancer	9.65e-06	0.00011	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—EGFR—colon cancer	9.61e-06	0.00011	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—colon cancer	9.6e-06	0.00011	CbGpPWpGaD
Dabrafenib—BRAF—Disease—CDKN1A—colon cancer	9.59e-06	0.00011	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—KRAS—colon cancer	9.45e-06	0.000108	CbGpPWpGaD
Dabrafenib—RAF1—Disease—BRAF—colon cancer	9.4e-06	0.000108	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—TP53—colon cancer	9.33e-06	0.000107	CbGpPWpGaD
Dabrafenib—BRAF—Disease—EP300—colon cancer	9.13e-06	0.000104	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—HRAS—colon cancer	9.1e-06	0.000104	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—KRAS—colon cancer	9.08e-06	0.000104	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—HRAS—colon cancer	8.93e-06	0.000102	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—PTGS2—colon cancer	8.91e-06	0.000102	CbGpPWpGaD
Dabrafenib—BRAF—Disease—SRC—colon cancer	8.87e-06	0.000102	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—PIK3CA—colon cancer	8.69e-06	9.95e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—NRAS—colon cancer	8.54e-06	9.78e-05	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—PIK3CA—colon cancer	8.34e-06	9.55e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	8.27e-06	9.47e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—colon cancer	8.1e-06	9.28e-05	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—HRAS—colon cancer	8.04e-06	9.2e-05	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—AKT1—colon cancer	8.03e-06	9.2e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—MYC—colon cancer	7.95e-06	9.11e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—TGFB1—colon cancer	7.93e-06	9.08e-05	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—AKT1—colon cancer	7.88e-06	9.02e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—EGFR—colon cancer	7.78e-06	8.91e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	7.73e-06	8.85e-05	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—HRAS—colon cancer	7.72e-06	8.84e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—FGFR3—colon cancer	7.63e-06	8.73e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PPARG—colon cancer	7.61e-06	8.72e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—PTGS2—colon cancer	7.59e-06	8.69e-05	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—EP300—colon cancer	7.41e-06	8.49e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CTNNB1—colon cancer	7.36e-06	8.42e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—KRAS—colon cancer	7.35e-06	8.41e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CDKN1A—colon cancer	7.19e-06	8.23e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CASP3—colon cancer	7.13e-06	8.17e-05	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—AKT1—colon cancer	7.1e-06	8.12e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PPARG—colon cancer	7.05e-06	8.07e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—APC—colon cancer	7e-06	8.02e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—NRAS—colon cancer	7e-06	8.02e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CCND1—colon cancer	6.94e-06	7.95e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CTNNB1—colon cancer	6.88e-06	7.87e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—EP300—colon cancer	6.84e-06	7.83e-05	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—AKT1—colon cancer	6.81e-06	7.8e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—CTNNB1—colon cancer	6.79e-06	7.78e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—PIK3CA—colon cancer	6.75e-06	7.73e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CDKN1A—colon cancer	6.72e-06	7.69e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—SRC—colon cancer	6.65e-06	7.61e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—CDKN1A—colon cancer	6.64e-06	7.6e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—BRAF—colon cancer	6.58e-06	7.54e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—EP300—colon cancer	6.43e-06	7.36e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—NRAS—colon cancer	6.4e-06	7.33e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—EP300—colon cancer	6.39e-06	7.32e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—EGFR—colon cancer	6.38e-06	7.3e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—EP300—colon cancer	6.31e-06	7.23e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—ABCB1—colon cancer	6.29e-06	7.2e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—HRAS—colon cancer	6.25e-06	7.15e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—SRC—colon cancer	6.21e-06	7.12e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—TYMS—colon cancer	6.18e-06	7.07e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—SRC—colon cancer	6.14e-06	7.03e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—VEGFA—colon cancer	6.05e-06	6.93e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—KRAS—colon cancer	6.03e-06	6.9e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PTGS2—colon cancer	5.99e-06	6.86e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—NRAS—colon cancer	5.98e-06	6.85e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—NRAS—colon cancer	5.91e-06	6.76e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—EGFR—colon cancer	5.83e-06	6.67e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—MYC—colon cancer	5.57e-06	6.38e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—TGFB1—colon cancer	5.56e-06	6.36e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PTGS2—colon cancer	5.55e-06	6.35e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—PIK3CA—colon cancer	5.54e-06	6.34e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—AKT1—colon cancer	5.52e-06	6.31e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—KRAS—colon cancer	5.51e-06	6.31e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—MYC—colon cancer	5.5e-06	6.3e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—TGFB1—colon cancer	5.49e-06	6.28e-05	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—PIK3CA—colon cancer	5.48e-06	6.28e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—EGFR—colon cancer	5.45e-06	6.24e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—EGFR—colon cancer	5.38e-06	6.16e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—TYMS—colon cancer	5.38e-06	6.16e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—KRAS—colon cancer	5.15e-06	5.89e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—HRAS—colon cancer	5.12e-06	5.87e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—KRAS—colon cancer	5.08e-06	5.82e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—PIK3CA—colon cancer	5.06e-06	5.79e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—EP300—colon cancer	4.98e-06	5.7e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CASP3—colon cancer	4.93e-06	5.65e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CCND1—colon cancer	4.8e-06	5.5e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CTNNB1—colon cancer	4.76e-06	5.45e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	4.75e-06	5.44e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—PIK3CA—colon cancer	4.73e-06	5.41e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—HRAS—colon cancer	4.68e-06	5.36e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—PIK3CA—colon cancer	4.67e-06	5.35e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CDKN1A—colon cancer	4.65e-06	5.32e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—EP300—colon cancer	4.61e-06	5.28e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—TP53—colon cancer	4.57e-06	5.24e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—AKT1—colon cancer	4.52e-06	5.18e-05	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—AKT1—colon cancer	4.48e-06	5.13e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—EP300—colon cancer	4.42e-06	5.06e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PPARG—colon cancer	4.37e-06	5.01e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—HRAS—colon cancer	4.37e-06	5.01e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—HRAS—colon cancer	4.32e-06	4.95e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—SRC—colon cancer	4.3e-06	4.92e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—VEGFA—colon cancer	4.19e-06	4.8e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—NRAS—colon cancer	4.14e-06	4.74e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—AKT1—colon cancer	4.13e-06	4.73e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—AKT1—colon cancer	3.86e-06	4.42e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—MYC—colon cancer	3.85e-06	4.41e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—TGFB1—colon cancer	3.84e-06	4.4e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—AKT1—colon cancer	3.82e-06	4.37e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PPARG—colon cancer	3.81e-06	4.36e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—EGFR—colon cancer	3.77e-06	4.32e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PIK3CA—colon cancer	3.68e-06	4.22e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—KRAS—colon cancer	3.56e-06	4.08e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PTGS2—colon cancer	3.44e-06	3.94e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PIK3CA—colon cancer	3.41e-06	3.91e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ABCB1—colon cancer	3.38e-06	3.86e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—TYMS—colon cancer	3.31e-06	3.8e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PIK3CA—colon cancer	3.27e-06	3.75e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—TP53—colon cancer	3.16e-06	3.62e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—HRAS—colon cancer	3.03e-06	3.46e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—AKT1—colon cancer	3.01e-06	3.45e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PTGS2—colon cancer	3e-06	3.43e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—EP300—colon cancer	2.86e-06	3.28e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—AKT1—colon cancer	2.79e-06	3.19e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—AKT1—colon cancer	2.67e-06	3.06e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—EP300—colon cancer	2.49e-06	2.86e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PPARG—colon cancer	2.35e-06	2.69e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PIK3CA—colon cancer	2.12e-06	2.42e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PTGS2—colon cancer	1.85e-06	2.12e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PIK3CA—colon cancer	1.84e-06	2.11e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—AKT1—colon cancer	1.73e-06	1.98e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—EP300—colon cancer	1.54e-06	1.76e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—AKT1—colon cancer	1.51e-06	1.73e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PIK3CA—colon cancer	1.14e-06	1.3e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—AKT1—colon cancer	9.28e-07	1.06e-05	CbGpPWpGaD
